Teva names Oberman as CEO of Teva Americas Generics
Teva Pharmaceutical, a global pharmaceutical company based in Israel, has made changes to its executive leadership team.
Allan Oberman, senior vice president of North America Generic Pharmaceuticals of Teva, has been appointed president and CEO of Teva Americas Generics as part of an orderly management succession. In his new role, Oberman will report directly to Jeremy Levin, president and CEO of Teva, and have continued responsibility for North America Generics, as well as overall management of Teva's Latin American businesses.
The company also announced the appointment of Jill DeSimone to the newly created position of senior vice president and general manager of Teva Global Women's Health, overseeing all aspects of Teva's Women's Health franchise.
"These changes are part of our ongoing process to build a premier leadership team and reshape Teva. Allan brings extensive experience in global generics to the company's Americas teams. Jill brings a great track record and many years of experience in building franchises in specialty medicine,” said Levin. “These changes underlie our commitment to build, in a disciplined fashion, a world class business and provide much needed medicines to patients around the world."
Teva also announced that William S. Marth will step down as president and CEO of Teva Americas effective immediately and retire at the end of 2013. Marth will serve as a senior advisor to Levin until his retirement.
"We greatly appreciate the contributions that Bill has made to Teva over the years, most recently leading the Teva businesses in the Americas,” said Levin. “During this time, the company experienced significant growth. We thank him for his tremendous service to the company and look forward to working with him over the next year in his new capacity as a core advisor.”